HRP20130203T1 - Postupak za lijeäśenje sindroma iritabilnog crijeva zbog prevladavajuä†eg zatvora - Google Patents

Postupak za lijeäśenje sindroma iritabilnog crijeva zbog prevladavajuä†eg zatvora Download PDF

Info

Publication number
HRP20130203T1
HRP20130203T1 HRP20130203TT HRP20130203T HRP20130203T1 HR P20130203 T1 HRP20130203 T1 HR P20130203T1 HR P20130203T T HRP20130203T T HR P20130203TT HR P20130203 T HRP20130203 T HR P20130203T HR P20130203 T1 HRP20130203 T1 HR P20130203T1
Authority
HR
Croatia
Prior art keywords
treatment
amount
constipation
bowel syndrome
irritable bowel
Prior art date
Application number
HRP20130203TT
Other languages
English (en)
Inventor
Barry Quart
David Rosenbaum
Original Assignee
Napo Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Napo Pharmaceuticals, Inc. filed Critical Napo Pharmaceuticals, Inc.
Publication of HRP20130203T1 publication Critical patent/HRP20130203T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (6)

1. Količina krofelemera koja je učinkovita za liječenje c-IBS naznačena time da je za uporabu kod liječenja sindroma iritabilnog crijeva zbog prevladavajućeg zatvora (c-IBS).
2. Količina za uporabu prema zahtjevu 1, naznačena time da je krofelemer fomuliran za oralno davanje u količini od između 250 mg dnevno i 4000 mg dnevno.
3. Količina za uporabu prema zahtjevu 1, naznačena time da se liječenje sastoji od smanjenja jednog ili više simptoma c-IBS.
4. Količina za uporabu prema zahtjevu 3, naznačena time da simptom je bol ili neugoda u abdomenu.
5. Količina za uporabu prema zahtjevu 3, naznačena time da simptom je zatvor ili frekvencija stolice koja je rjeđa od normalne.
6. Količina krofelemera koja je učinkovita za liječenje a-IBS naznačena time da je za uporabu kod liječenja izmjenjujućeg sindroma iritabilnog crijeva zbog prevladavajućeg zatvora/prevladavajućeg proljeva (a-IBS).
HRP20130203TT 2006-05-01 2013-03-08 Postupak za lijeäśenje sindroma iritabilnog crijeva zbog prevladavajuä†eg zatvora HRP20130203T1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79707606P 2006-05-01 2006-05-01

Publications (1)

Publication Number Publication Date
HRP20130203T1 true HRP20130203T1 (hr) 2013-04-30

Family

ID=38668465

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130203TT HRP20130203T1 (hr) 2006-05-01 2013-03-08 Postupak za lijeäśenje sindroma iritabilnog crijeva zbog prevladavajuä†eg zatvora

Country Status (19)

Country Link
US (3) US7556831B2 (hr)
EP (2) EP2015639A4 (hr)
JP (2) JP2009535419A (hr)
KR (2) KR20130067317A (hr)
AU (1) AU2007248182B2 (hr)
CA (1) CA2650022C (hr)
CY (1) CY1113723T1 (hr)
DK (1) DK2241318T3 (hr)
ES (1) ES2401366T3 (hr)
HK (1) HK1143541A1 (hr)
HR (1) HRP20130203T1 (hr)
MX (1) MX2008013768A (hr)
NZ (3) NZ572049A (hr)
PL (1) PL2241318T3 (hr)
PT (1) PT2241318E (hr)
RS (1) RS52678B (hr)
SG (2) SG195538A1 (hr)
SI (1) SI2241318T1 (hr)
WO (1) WO2007130892A2 (hr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2007130892A2 (en) 2006-05-01 2007-11-15 Napo Pharmaceuticals, Inc. Method for treatment of constipation-predominant irritable bowel syndrome
CA2657803C (en) 2006-05-01 2019-01-08 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
US8436051B2 (en) * 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US8734867B2 (en) * 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
WO2010033626A1 (en) * 2008-09-19 2010-03-25 Institute For Oneworld Health Compounds, compositions and methods comprising imidazole and triazole derivatives
JP4565219B2 (ja) * 2008-12-26 2010-10-20 アサヒビール株式会社 ポリフェノール含有顆粒またはポリフェノール含有チュアブル錠剤およびその製造方法
JP2012519690A (ja) 2009-03-04 2012-08-30 メタアクティブ、インコーポレイテッド 生体分子の部位活性化複合体形成方法及び材料
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2485596A4 (en) * 2009-10-06 2013-07-17 Univ California METHODS OF TREATING DISEASES BY PROMAHOCYANIDINE OLIGOMERS SUCH AS CROFELEMER
WO2012058664A1 (en) * 2010-10-31 2012-05-03 Salix Pharmaceuticals, Ltd. Methods and compositions for treating hiv-associated diarrhea
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
US20120329736A1 (en) * 2011-06-24 2012-12-27 Huang Alexander L Treatment for gastrointestinal disorders using a selective, site-activated binding system
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
EP2922557B1 (en) 2012-11-21 2017-10-04 KBS Research, LLC Herbal supplements and methods of use thereof
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms
US9510880B2 (en) 2013-08-13 2016-12-06 Zimmer, Inc. Polyaxial locking mechanism
WO2015184109A1 (en) * 2014-05-29 2015-12-03 Jaguar Animal Health, Inc. Methods of treating diarrhea in adult non-human animals
US10282369B2 (en) * 2017-03-08 2019-05-07 Centri Technology, Inc. Fast indexing and searching of encoded documents
JOP20190275A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
US11447811B2 (en) * 2017-07-17 2022-09-20 smartDNA Pty Ltd Method of diagnosing a dysbiosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE446940B (sv) 1983-02-16 1986-10-20 Carl Axel Virdalm Medel for bekempande av sjukdomstillstand i matsmeltningsapparaten innehallande skal eller ytterdelar av ber eller frukter
US4698360B1 (en) 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
DE3564370D1 (en) 1985-08-30 1988-09-22 Nestle Sa Dietetic product with depurating and antidiarrheal activity and process for its preparation
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
SI9011933A (sl) 1990-10-15 1998-06-30 TANIN SEVNICA Kemična industrija p.o. Kostanjev taninski ekstrakt, postopek za njegovo pridobivanje in njegova uporaba
US5234922A (en) 1992-09-28 1993-08-10 University Of Iowa Research Foundation Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea
CA2269078C (en) 1996-10-16 2012-01-24 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
AU6967198A (en) 1997-04-10 1998-10-30 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea
CN1215561A (zh) * 1997-10-27 1999-05-05 邢文海 保健茶
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
CN1159054C (zh) 2002-01-22 2004-07-28 随志化 通腑止泻剂
US20040063695A1 (en) 2002-09-30 2004-04-01 Alan Verkman Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US7208183B2 (en) 2002-10-05 2007-04-24 Bobrowski Paul J Methods and preparations of the latex from the croton species
US7303772B2 (en) * 2005-11-10 2007-12-04 Olalde Rangel Jose Angel Synergistic phytoceutical compositions
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2007130892A2 (en) 2006-05-01 2007-11-15 Napo Pharmaceuticals, Inc. Method for treatment of constipation-predominant irritable bowel syndrome
CA2657803C (en) 2006-05-01 2019-01-08 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
EP2485596A4 (en) 2009-10-06 2013-07-17 Univ California METHODS OF TREATING DISEASES BY PROMAHOCYANIDINE OLIGOMERS SUCH AS CROFELEMER
WO2012058664A1 (en) 2010-10-31 2012-05-03 Salix Pharmaceuticals, Ltd. Methods and compositions for treating hiv-associated diarrhea
WO2014088629A1 (en) 2012-12-07 2014-06-12 Salix Pharmaceuticals, Ltd Methods and compositions for treating hiv-associated diarrhea

Also Published As

Publication number Publication date
PT2241318E (pt) 2013-03-18
JP2014058548A (ja) 2014-04-03
EP2015639A4 (en) 2009-11-25
NZ572049A (en) 2012-08-31
KR20090009292A (ko) 2009-01-22
ES2401366T3 (es) 2013-04-19
CY1113723T1 (el) 2016-06-22
US9138450B2 (en) 2015-09-22
US7556831B2 (en) 2009-07-07
US20120128797A1 (en) 2012-05-24
US20080031983A1 (en) 2008-02-07
RS52678B (en) 2013-06-28
AU2007248182B2 (en) 2013-05-23
HK1143541A1 (en) 2011-01-07
WO2007130892A3 (en) 2008-10-30
KR20130067317A (ko) 2013-06-21
CA2650022A1 (en) 2007-11-15
EP2241318B1 (en) 2012-12-19
US8067041B2 (en) 2011-11-29
NZ609280A (en) 2014-09-26
AU2007248182A1 (en) 2007-11-15
SG161259A1 (en) 2010-05-27
DK2241318T3 (da) 2013-01-21
US20090238901A1 (en) 2009-09-24
CA2650022C (en) 2017-05-16
MX2008013768A (es) 2009-02-03
JP2009535419A (ja) 2009-10-01
SG195538A1 (en) 2013-12-30
PL2241318T3 (pl) 2013-05-31
EP2015639A2 (en) 2009-01-21
NZ595679A (en) 2013-04-26
SI2241318T1 (sl) 2013-04-30
WO2007130892A2 (en) 2007-11-15
EP2241318A1 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
HRP20130203T1 (hr) Postupak za lijeäśenje sindroma iritabilnog crijeva zbog prevladavajuä†eg zatvora
GEP20156281B (en) Orally administered corticosteroid compositions
HRP20121072T1 (hr) Postupci za davanje tetrahidrobiopterina, povezani pripravci i postupci mjerenja
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
NZ612504A (en) Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
UA93201C2 (ru) АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1
PH12013501791B1 (en) Uses of dpp-iv inhibitors
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
HK1126119A1 (en) Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3- propanaediol derivative as active ingredient, and its use in manufacture of medicines for preventing or treating inflammatory bowel disease 2--13-
NZ595262A (en) Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
MX2023008408A (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
NZ594022A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
RS52956B (en) CANCER TREATMENT COMPOSITIONS
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2007136845A3 (en) Low-dose doxepin for treatment of sleep disorders in elderly patients
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
HRP20150949T1 (hr) UPORABA 24-norUDCA
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
IL194880A (en) Aminazole amine derivatives, their use in the treatment of diseases and pharmaceuticals containing them
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2007041388A3 (en) Prevention and treatment of hearing disorders